NCT03737123View on ClinicalTrials.gov

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 19, 2018

Primary Completion Date

March 8, 2022

Study Completion Date

May 18, 2022

Conditions
Urothelial Carcinoma
Interventions
DRUG

Carboplatin

Carboplatin AUC 4 IV Day 1 of each 21 day cycle

DRUG

Gemcitabine

Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle

DRUG

Atezolizumab

Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle

DRUG

Docetaxel

Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.

Trial Locations (4)

45267

University of Cincinnati Cancer Institute, Cincinnati

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

68114

Nebraska Methodist Hosptial, Omaha

87102

University of New Mexico Comprehensive Cancer Center, Albuquerque

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Indiana University School of Medicine

OTHER

lead

Nabil Adra

OTHER